Syndax Pharmaceuticals (SNDX) Is Up 13.6% After FDA Approval and NCCN Inclusion of Revvvi Forge – Has the Bull Case Changed?

• In late November, Syndax Pharmaceuticals announced that its key therapy Revvvi Forge received FDA approval for relapse-refractory NPM1-mutated AML and was added to the NCCN guidelines, expanding its treatment options and addressable market.
• This development coincided with strong commercial performance, as Syndax reported robust patient uptake and increased revenue for both Revvvi Forge and Nick Timbo.
• We'll now explore how the recent FDA approval and guideline inclusion for Revvvi Forge impacts Syndax's overall investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

Syndax Pharmaceuticals Investment Narrative Recap

To be a shareholder in Syndax Pharmaceuticals, you need to believe in continued, robust adoption and label expansion for its two leading therapies, Revuforj and Niktimvo. The recent FDA approval and NCCN guideline inclusion for Revuforj in relapse-refractory NPM1-mutated AML is a significant short-term catalyst, as it helps mitigate the largest near-term risk: the company's substantial reliance on these two assets for future growth.

Among recent corporate announcements, the October 2025 FDA approval of Revuforj for NPM1-mutated AML stands out as most relevant. This development directly addresses prior investor concerns around regulatory risk and label expansion, acting as a key milestone supporting stronger uptake and commercial performance, a critical driver highlighted in Syndax's latest earnings results.

Yet, in contrast, investors should be aware that heavy dependence on Revuforj and Niktimvo brings heightened risk if...

Read the full narrative on Syndax Pharmaceuticals (it's free!)

Syndax Pharmaceuticals' outlook forecasts $603.4 million in revenue and $43.5 million in earnings by 2028. This implies a 97.8% annual revenue growth rate and a $378.5 million increase in earnings from current earnings of -$335.0 million.

Uncover how Syndax Pharmaceuticals' forecasts yield a $38.31 fair value, a 93% upside to its current price.

Exploring Other Perspectives

Six individual fair value estimates from the Simply Wall St Community span US$9.64 to US$141.55. While opinions vary widely, many are factoring in the company's need for further clinical and commercial progress before broader confidence can set in.

Explore 6 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth over 7x more than the current price!

Build Your Own Syndax Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 35 companies in the world exploring or producing it. Find the list for free.
• We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com